In Gene Therapy, the Company initiated two trials with gene therapy partners: SRP-9001-104 Phase 1b trial in Duchenne Muscular Dystrophy (DMD) with Sarepta Therapeutics, Inc. (Nasdaq: SRPT) and ...

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) yesterday and set a ...

Seeking Alpha analyst Terry Chrisomalis regards Viking Therapeutics as the most attractive M&A candidate in 2025, bolstered ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that ...

The upside in Sarepta's share price can be attributed to the encouraging sales performance of its DMD gene therapy, which has demonstrated blockbuster potential.

The research team at RBC Capital Markets published their top 30 global stock ideas for 2025, ...

LX-2006 is under development for the treatment of cardiomyopathy associated with Friedreich’s Ataxia. The drug candidate consists of Adeno-associated virus (AAV) vector carrying frataxin gene and is ...

Dec. 18, 2024 — Until now, scientists have been unable to determine how metformin, a Type 2 diabetes medication that lowers blood sugar, works. A study provided direct evidence in mice that it ...

Jefferies analyst Andrew Tsai has maintained their bullish stance on SRPT stock, giving a Buy rating on December 19.Don't Miss Our New Year's ...

Marriage licenses issued by the Columbia County Clerk's Office during 2024. Landan Shawn Beams, 29, of Magnolia and Erin Kay ...

Precision Medicine Online readers were interested in stories about implementation challenges in the space, the first cell therapies for solid tumors, and cardiovascular drugs targeting Lp(a).

rohit sharma latest news Sarepta's innovative DMD therapy Vyondys 53 receives accelerated approval from the U.S. FDA Liquid biopsy: a new generation of early cancer screening method CAR-T out of favor ...